The latest biotech hoping to take advantage of the new emerging growth company category under the Jumpstart Our Business Startups (JOBS) Act of 2012, antibiotic developer Paratek Pharmaceuticals Inc. filed for an initial public offering (IPO) aiming to raise $92 million as it takes thrice partner-dumped omadacycline into Phase III testing on its own.
Drugs derived from the venom of unusual species is hardly a novelty in biotech. There's Amylin Pharmaceuticals Inc.'s Gila monster-derived diabetes drug Byetta (exenatide) and investigational drugs GxMTx4, a nontoxic peptide from spider venom from Rose Pharmaceuticals for Duchenne's muscular dystrophy, and Paion AG's recently divested desmoteplase, a plasminogen activator based on the saliva from a vampire bat.
Two weeks ago, Peregrine Pharmaceuticals Inc. was flying high. The Tustin, Calif.-based company surprised Wall Street with statistically significant interim survival data from its Phase IIb trial of cancer drug bavituximab and said it was in potentially lucrative partnering talks. But on Monday, the firm's shares lost three-fourths of their value as investors learned that those Phase II results might not turn out to be that impressive after all.
The latest firm launched by Third Rock Ventures, MyoKardia Inc., started its existence with a $38 million Series A financing, disclosed Thursday morning, to translate discoveries of mutations in the heart muscle into personalized therapeutic approaches for treating genetic cardiomyopathy.
Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering.
Targacept Inc.'s TC-5619 missed its endpoint in a Phase II study in inattentive-predominant attention deficit hyperactivity disorder (iADHD), the latest in a string of disappointing news for its neuronal nicotinic receptor (NNR) pipeline.
Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering.
The recent spate of setbacks for competitors working in hepatitis C virus (HCV) has proved good news for Achillion Pharmaceuticals Inc., which took the opportunity to shore up its balance sheet with a $41.8 million offering.
The diabetes arsenal is chock full of marketed therapies – glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors and the so-called "glitazones" to name a few (though the latter has suffered from safety concerns over the past few years) – but the space has seen a shortage of promising new targets.
Barely three months after reporting solid Phase IIb data for EP-101, its aerosol therapy for chronic obstructive pulmonary disease (COPD), Elevation Pharmaceuticals Inc. is being snagged in a buyout by Sunovion Pharmaceuticals Inc. in a deal valued at up to $430 million.
